PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III clinical trials. The company is also developing PB1046 for pulmonary arterial hypertension and PB6440 for resistant hypertension.

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities. 

Looking for a new role? Please visit our careers page to find out more about our open jobs and benefits at https://phasebio.com/careers/

SFJ Pharmaceuticals

AstraZeneca

Hatteras Venture Partners

Syno Capital

Cormorant Asset Management

Fletcher Spaght, Inc.

Rock Springs Capital

Johnson & Johnson Innovation – JJDC

Mountain Group Capital

New Enterprise Associates

PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

COM:PHASEBIO

PhaseBio Pharmaceuticals, Inc.

Last Close

0.07

17/09 20:00

Volume Today

8.56M

Avg: -

Analysis Not Available